Merck KGaA in collaboration for better vaccines in developing countries

28 June 2016
merckkgaa-big

German life sciences and pharma company Merck KGaA (MRK: DE) has entered into a research agreement with South Korea’s International Vaccine Institute (IVI) to develop better purification processes.

The new collaboration is promised to improve manufacturing to deliver greater yield, allowing higher recovery and providing greater purity vaccines.

IVI is a non-profit international organization committed to the discovery, development and delivery of safe, effective and affordable vaccines for global public health.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical